Acorda Therapeutics Added to NASDAQ Biotech Index
16th Nov 2006, 16:03 GMT
Acorda Therapeutics has been selected for addition to the Nasdaq Biotech Index, which will be effective at the market's opening, 11/20/2006.
Latest news from Neurology News from StratCenter.com:
- Alzheimer's Foundation of America to Hold Nat'l Memory Screening Day
- Neurologix Announces Q3 Results
- Kensey Nash Announces Commencement of Carotid Pivotal Trial for TriActiv ProGuard System
- New Study Finds Everyday Activities Trigger Smoking Cravings
- Neurobiological Technologies Review Issued by Scimitar Equity Research
- AQA Adopts Additional Standard Quality Measures for Practitioners in 25 Surgical and Medical Specialties
- StemCells' product transplanted in early clinical trial
- StemCells Begins Study on Rare Disease
- StemCells Announces 1st Human Neural Stem Cell Transplant
- Vanda Pharmaceuticals' VEC-162 Demonstrates Positive Results in a Phase III Transient Insomnia Clinical Trial